Dexlansoprazole

Contraindicated

Dexlansoprazole Rilpivirine Edurant Reduced oral rilpivirine exposure, reduced efficacy of rilpivirine and an increased loss of virologic response Details

Major

Dexlansoprazole Acalabrutinib Calquence Reduced acalabrutinib exposure Details Dexlansoprazole Belumosudil Rezurock Reduced belumosudil exposure Details Dexlansoprazole Atezolizumab Injection Tecentriq Impaired efficacy of atezolizumab Details Dexlansoprazole Bosutinib Bosulif Reduced bosutinib exposure Details Dexlansoprazole Capecitabine Xeloda Reduction in capecitabine efficacy Details Dexlansoprazole Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Dexlansoprazole Dacomitinib Vizimpro Reduced dacomitinib exposure Details Dexlansoprazole Dasatinib Phyrago Reduced dasatinib exposure Details Dexlansoprazole Amphetamine Dexedrine Increased exposure to amphetamine Details Dexlansoprazole Apalutamide Erleada Reduced CYP2C19 substrate exposure Details Dexlansoprazole Atazanavir Reyataz Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Dexlansoprazole Atezolizumab Tecentriq Impaired efficacy of atezolizumab Details Dexlansoprazole Benzphetamine Increased exposure to amphetamine Details Dexlansoprazole Cannabidiol Epidiolex Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Dexlansoprazole Carbamazepine Carbatrol Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Dexlansoprazole Cefuroxime Axetil Decreased cefuroxime axetil exposure Details Dexlansoprazole Defactinib Reduced defactinib exposure and an reduced efficacy of defactinib Details Dexlansoprazole Dextroamphetamine Dexedrine Increased exposure to amphetamine Details Dexlansoprazole Erlotinib Tarceva Reduced erlotinib exposure Details Dexlansoprazole Fedratinib Inrebic Increased CYP2C19 substrate exposure Details Dexlansoprazole Fluconazole Diflucan Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse events Details Dexlansoprazole Gefitinib Iressa Decreased exposure of gefitinib Details Dexlansoprazole Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Dexlansoprazole Ketoconazole Extina Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Dexlansoprazole Ledipasvir Decreased ledipasvir exposure and loss of efficacy Details Dexlansoprazole Levoketoconazole Recorlev Reduced levoketoconazole exposure Details Dexlansoprazole Lisdexamfetamine Arynta Increased exposure to amphetamine Details Dexlansoprazole Lonafarnib Zokinvy Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Dexlansoprazole Methamphetamine Desoxyn Increased exposure to amphetamine Details Dexlansoprazole Methotrexate Jylamvo Increased risk of methotrexate toxicity Details Dexlansoprazole Methylphenidate Adhansia XR® Altered pharmacodynamic and changes in release profile of methylphenidate Details Dexlansoprazole Mycophenolate Mofetil Reduced mycophenolic acid exposure Details Dexlansoprazole Nelfinavir Viracept Decreased nelfinavir plasma concentrations and risk of diminished therapeutic effect of nelfinavir Details Dexlansoprazole Neratinib Nerlynx Decreased neratinib solubility, absorption, and exposure Details Dexlansoprazole Nilotinib Reduced nilotinib exposure and reduced efficacy of nilotinib Details Dexlansoprazole Nirogacestat Ogsiveo Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Dexlansoprazole Nivolumab Opdivo Reduced efficacy of nivolumab Details Dexlansoprazole Octreotide Bynfezia Decreased octreotide bioavailability Details Dexlansoprazole Palbociclib Ibrance Reduced efficacy of palbociclib Details